ClinicalTrials.gg
WithdrawnNCT04138485Updated Nov 17, 2020

Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

A Phase 2 interventional study of IgPro10 and Placebo in Diffuse Cutaneous Systemic Sclerosis, sponsored by CSL Behring. Withdrawn at 77 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-17.

Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Due to business reasons, not safety issues

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 153 studies in Scleroderma, Diffuse with a site in United States — 29 open to participants now, 39 under way, 5 of them phase 3. Scleroderma, Diffuse · United States.

Enrollment
114th of 120
0 · median 29
Started
2019
with 5 others
Phase 2
41 of 153
8 open now
Registered
98th of 153
by date

Among the 153 studies in Scleroderma, Diffuse with a site in United States, this one is the 114th largest by enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2019, is one of 41 in phase 2, and was the 98th registered.

Scleroderma, Diffuse

310 studies on the registry are indexed under Scleroderma, Diffuse; 76 are open to participants now.

Browse Scleroderma, Diffuse studies →

Open to participants now

29 of the 153 studies in Scleroderma, Diffuse with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Scleroderma, Diffuse studies recruiting now, 28 (51%) set no upper age limit and 20 (36%) stop at 75 or younger; 10 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Scleroderma, Diffuse with a site in United States, or all of them as a file.
02

Study summary

This randomized, multicenter, double-blind (DB), placebo controlled, phase 2 study will evaluate the efficacy and safety of IgPro10. The DB Treatment Period will be followed by a 24-week Open-label (OL) Treatment Period.

Eligible subjects will be randomized at Baseline in a 2:1 ratio of treatment IgPro10 or placebo in the DB Treatment Period. All subjects who enter OL Treatment Period will receive IgPro10.

03

Conditions studied

  • Diffuse Cutaneous Systemic Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Age ≥18 years (male or female) at time of providing written
  • Documented diagnosis of SSc according to ACR / EULAR criteria 2013
  • mRSS ≥ 15 and ≤ 45
  • Disease duration ≤ 5 years defined as the time from the first non-Raynaud's phenomenon manifestation
  • Subjects within first 18 months of disease duration from first non-Raynaud's phenomenon manifestation.

Exclusion criteria

Exclusion Criteria:

  • Primary rheumatic disease other than dcSSc, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disorder, polymyositis, and dermatomyositis, as determined by the investigator Note: Subjects with fibromyalgia, secondary Sjogren's syndrome, and scleroderma-associated myopathy or myositis at Screening are not excluded
  • Positive anti-centromere autoantibodies at Screening
  • Evidence of severe chronic kidney disease with estimated \< 45 mL/min/1.73 m2 (as calculated by the Chronic Kidney Disease Epidemiology Collaboration equation) or receiving dialysis. Additionally, subjects with current confirmed diagnosis of diabetes mellitus and requiring medication, with eGFR \< 90 mL/min/1.73m2 will be excluded from the study.
  • History of documented thrombotic episode eg, PE, DVT, myocardial infarction, thromboembolic stroke at any time Note: past superficial thrombophlebitis more than two years from Screening is not exclusionary
  • Documented thrombophilic abnormalities including blood hyperviscosity, protein S or protein C deficiency, anti-thrombin-3 deficiency, plasminogen deficiency, antiphospholipid syndrome, Factor V Leiden mutation, dysfibrinogenemia, or prothrombin G20210A mutation
  • Greater than 3 specified current risk factors for TEEs (documented and currents conditions): atrial fibrillation, coronary disease, diabetes mellitus, dyslipidemia, hypertension, obesity ( ≥ 30 kg/m2), recent significant trauma, and immobility (wheelchair-bound or bedridden)
  • Ongoing active serious infection at Screening (including, but not limited to, pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess)
  • in the past 2 years, except for non-melanoma skin cancer, cervical carcinoma in situ, or other in situ cancer if it has been excised and treated within in the past year
  • Known hypoalbuminemia, protein-losing enteropathies, and any proteinuria (defined by total urine protein concentration > 0.2 g/L)
  • Known IgA deficiency or serum IgA level \< 5% lower limit of normal
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    IgPro10

    10% liquid formulation of human immunoglobulin for intravenous use

    Biological: IgPro10

  • Placebo comparator
    Placebo

    0.5% human albumin solution stabilized with 250 mmol/L L-proline

    Biological: Placebo

Interventions

  • BiologicalIgPro10

    10% liquid formulation of human immunoglobulin for IVIG

    Also known as: Human normal immunoglobulin

  • BiologicalPlacebo

    0.5% human albumin solution stabilized with 250 mmol/L L-proline

    Also known as: Albumin

06

What researchers measure

Primary outcomes

  1. Response on American College of Rheumatology Combined Response Index in Diffuse Systemic Sclerosis (ACR CRISS) score in IgPro10 vs Placebo

    Time frame: Over 48 weeks

Secondary outcomes

  1. Proportion of subjects meeting cardiopulmonary or renal failure criteria in ACR CRISS Step 1 events

    Time frame: Over 48 weeks

  2. Proportion of responders (ACR CRISS > 0.6)

    Time frame: Over 48 weeks

  3. Mean change from Baseline in Modified Rodnan Skin Score (mRSS)

    Time frame: Baseline and over48 weeks

  4. Mean change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI)

    Time frame: Baseline and over 48 weeks

  5. Mean change from Baseline in Forced Vital Capacity (FVC)% predicted

    Time frame: Baseline and over 48 weeks

  6. Mean change from Baseline in diffusing capacity of lung for carbon monoxide (DLCO)% predicted

    Time frame: Baseline and over 48 weeks

  7. Mean change from Baseline in Physician Global Assessment (MDGA)

    MDGA evaluates the overall impact of SSc on the participant as assessed by the physician on a 11-point Numeric rating scale scale from 0 (excellent) to 10 (extremely poor)

    Time frame: Baseline and over 48 weeks

  8. Mean change from Baseline in Patient Global Assessment (PGA)

    PGA evaluates the overall impact of SSc on the participant as assessed by the physician on a 11-point Numeric rating scale scale from 0 (excellent) to 10 (extremely poor)

    Time frame: Baseline and over 48 weeks

  9. Mean change from Baseline in UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 (UCLA SCTC GIT 2.0) total score and subscale

    This survey consists of 34 questions and items are scored on a scale of 0 (better health) to 3 (worse health). Scores are combined to form total score.

    Time frame: Baseline and over 48 weeks

  10. Mean change from Baseline in Scleroderma Skin Patient Reported Outcome (SSPRO) score in IgPro10 vs Placebo

    Time frame: Baseline and up to 48 weeks

  11. Proportion of responders in mRSS

    Response is decrease of mRSS ≥ 5 points and change of ≥ 25% from Baseline in IgPro10 vs Placebo

    Time frame: Up to 48 weeks

  12. Time to treatment failure (time from first infusion to time of first event) in IgPro10 vs Placebo

    Treatment failure - defined as occurrence of SSc associated complications in ACR CRISS step 1 events, digital ischemia (requiring hospitalization for IV prostacyclin, surgical intervention or amputation), serious gastrointestinal events (events requiring parenteral nutrition due to SSc -such as total parenteral nutrition or enteral nutrition), all-cause mortality

    Time frame: Over 48 weeks

  13. Proportion of subjects with events at Week 48 in IgPro10 vs Placebo

    Events defined as occurrence of SSc associated complications in ACR CRISS step 1 events, digital ischemia (requiring hospitalization for IV prostacyclin, surgical intervention or amputation), serious gastrointestinal events (events requiring parenteral nutrition due to SSc -such as total parenteral nutrition or enteral nutrition), all -cause mortality

    Time frame: Over 48 weeks

  14. Mean change from Baseline in Cochin Hand Function Scale in IgPro10 vs Placebo

    Time frame: Baseline and over 48 weeks

  15. Mean change from Baseline in Scleroderma Health Assessment Questionnaire (SHAQ) score in IgPro10 vs Placebo

    Time frame: Baseline and over 48 weeks

  16. Mean change from baseline in muscle strength as measured by Manual Muscle Testing 8 (MMT) in IgPro10 vs Placebo

    Time frame: Baseline and over 48 weeks

  17. Number of subjects with adverse events (AEs) including any AEs, treatment-emergent AEs (TEAEs), serious AEs (SAEs), and AEs of special interest (AESIs)

    Time frame: Over 48 weeks

  18. Percentage of subjects with AEs, TEAEs, SAEs, AESIs

    Time frame: Over 48 weeks

  19. Concentration of serum trough IgG levels at Baseline and prior to first infusion

    Time frame: Baseline and up to 72 weeks

  20. Mean change from Baseline in Modified Rodnan skin score (mRSS)

    Time frame: Baseline and over 72 weeks

  21. Mean change from Baseline in Patient global assessment (PGA)

    Time frame: Baseline and over 72 weeks

  22. Proportion of responders (ACR CRISS > 0.6)

    Time frame: Over 72 weeks

  23. Mean change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI)

    Time frame: Baseline and over 72 weeks

  24. Mean change from Baseline in Forced Vital Capacity (FVC)% predicted

    Time frame: Baseline and over 72 weeks

  25. Mean change from Baseline in diffusing capacity of lung for carbon monoxide (DLCO)% predicted

    Time frame: Baseline and over 72 weeks

  26. Mean change from Baseline in Physician Global Assessment (MDGA)

    Time frame: Baseline and over 72 weeks

  27. Number of subjects with adverse events (AEs) including any AEs, treatment-emergent AEs (TEAEs), serious AEs (SAEs), and AEs of special interest (AESIs)

    Time frame: Over 72 weeks

  28. Percentage of subjects with AEs, TEAEs, SAEs, AESIs

    Time frame: Over 72 weeks

07

Study locations

77 sites
  • Mayo Clinic Arizona - Scottsdale
    Scottsdale, Arizona 85259, United States
  • Pacific Arthritis Care Center
    Los Angeles, California 90045, United States
  • University of California
    Los Angeles, California 90095, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Lombardi Cancer Center-Georgetown University
    Washington, District of Columbia 20007, United States
  • Alliance for Multispecialty Research
    Wichita, Kansas 67207, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Louisiana State University Health Sciences Center
    Shreveport, Louisiana 71103, United States
  • John Hopkins Bayview Medical Center
    Baltimore, Maryland 21287, United States
  • Boston University Amyloidosis Center
    Boston, Massachusetts 02118, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48108, United States
  • Rutgers Clinical Research Center
    New Brunswick, New Jersey 08901, United States
  • Northwell Health
    Great Neck, New York 11021, United States
  • Hospital For Special Surgery
    New York, New York 10021, United States
  • Cleveland Clinic - Taussig Cancer Center
    Cleveland, Ohio 44195, United States
  • Altoona Center For Research
    Duncansville, Pennsylvania 16635, United States
  • University of Pennsylvania - Perelman Center
    Philadelphia, Pennsylvania 19104, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • The University Of Texas Medical School At Houston (Utms)
    Houston, Texas 77030, United States
  • APRILLUS Asistencia e Investigacion Clinica
    Buenos Aires, C1194AAO, Argentina
  • Hospital Italiano de Buenos Aires
    Buenos Aires, S2000SDV, Argentina
  • Hospital Militar Central
    Ciudad Autonoma de Buenos Aires, C1426AAL, Argentina
  • Sanatorio Parque S.A y Consultorios Externos Asociados
    Rosario, C1181ACH, Argentina
  • John Hunter Hospital / Autoimmune Resource and Research Centre
    New Lambton Heights, New South Wales 2305, Australia
  • PARC Clinical Research
    Adelaide, South Australia 5005, Australia
  • UZ Gent
    Gent, 9000, Belgium
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Mount Sinai Hospital, The Rebecca Macdonald Centre For Arthritis
    Toronto, M5T 3L9, Canada
  • CHU de Caen
    Caen, 14000, France
  • CHRU de Lille Hopital Huriez
    Lille Cedex, 59037, France
  • Internal Medicine, Nantes University Hospital
    Nantes, 44000, France
  • Assistance Publique - Hopitaux de Paris (AP-HP)
    Paris, 75014, France
  • CHU de Rennes-Hopital Sud
    Rennes, 35203, France
  • Centre Hospitalier Universitaire de Rouen-Hopital
    Rouen cedex, 76000, France
  • CHU Hautepierre
    Strasbourg, 67098, France
  • Kerckhoff Klinik GmbH, Abteilung für Rheumatologie und Klinische Immunologie Rheumatologie
    Bad Nauheim, 61231, Germany
  • Charite - Universitaetsmedizin Berlin - Campus Charite Mitte
    Berlin, 10117, Germany
  • Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)
    Berlin, 10117, Germany
  • Universitaetsklinikum Freiburg- Klinik fuer Rheumatologie und Klinische Immunologie
    Freiburg, 79106, Germany
  • University Hospital of Cologne
    Köln, 50937, Germany
  • Universitaetsmedizin der Johannes Gutenberg
    Mainz, 55131, Germany
  • University Hospital Of Tuebingen
    Tuebingen, 72076, Germany
  • Universitaetsklinikum Ulm
    Ulm, 89081, Germany
  • Hospital St. Josef
    Wuppertal, 42105, Germany
  • Universita degli Study di Ancona
    Ancona, 60121, Italy
  • Universita Degli Studi Di Bari Aldo Moro
    Bari, 70121, Italy
  • Universita degli Studi Di Brescia
    Brescia, 25123, Italy
  • Universita degli Studi Firenze
    Firenze, 50139, Italy
  • UOC Immunoreumatologia
    L'Aquila, 67100, Italy
  • Azienda Ospedaliera Gaetano Pini
    Milano, 20122, Italy
  • Modena University
    Modena, 41121, Italy
  • Universita degli Studi di Napoli Federico II
    Napoli, 80138, Italy
  • IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Dip.to Med. Sperimentale -Polic.Umberto I -Univ. La Sapienza
    Rome, 00161, Italy
  • Centro de Investigacion y Tratamiento Reumatologico S.C.
    Ciudad de México, 11850, Mexico
  • Centro Integral en Reumatologia, SA de CV
    Guadalajara, 44160, Mexico
  • Centro De Estudios De Investigation Basica Y Clinica S.C
    Jalisco, 44690, Mexico
  • Cliditer, S.A. DE C.V.
    Mexico City, 06700, Mexico
  • Instituto Nacional De Ciencias Medicas Y Nutricion
    Mexico, 14080, Mexico
  • Centro de Alta Especialidad en Reumatologia
    San Luis Potosi, 78213, Mexico
  • Uniwersytecki Szpital Kliniczny W Bialymstoku
    Bialystok, 15-369, Poland
  • University Clinical Centre, Medical University of Gdansk
    Gdańsk, 80-211, Poland
  • Samodzielny Publiczny Szpital Kliniczny
    Katowice, 40-635, Poland
  • Klinika Dermatologii Szpital im. Dzieciątka Jezus
    Warszawa, 00-001, Poland
  • Klinika i Poliklinika Układowych Chorób Tkanki Łącznej Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji
    Warszawa, 02-637, Poland
  • Complejo Hospitalario Universitario A Coruna
    A Coruna, 15006, Spain
  • Hospital Universitari Materno Infantil Vall Dhebron
    Barcelona, 08035, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28009, Spain
  • Hospital Univ 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Infanta Luisa Quirónsalud
    Sevilla, 41010, Spain
  • Hospital Universitari Dr.Peset
    Valencia, 46017, Spain
  • Cantonal Hospital St. Gallen - Klinik fuer Rheumatologie
    Saint Gallen, 9007, Switzerland
  • Countess of Chester Hospital
    Chester, CH2 1UL, United Kingdom
  • Chapel Allerton Hospital
    Leeds, LS7 4SA, United Kingdom
  • Royal Free Hospital-Royal Free London NHS Foundation Trust
    London, NW3 2QG, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systemic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.

Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Sep 2020, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2019
First posted
Oct 24, 2019
StartActual
Dec 20, 2019
Primary completionActual
Sep 16, 2020
CompletionActual
Sep 16, 2020
Last update
Nov 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04138485
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Oct 24, 2019
Start date
Dec 20, 2019
Primary completion
Sep 16, 2020
Completion
Sep 16, 2020
Last update
Nov 17, 2020

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IGPRO10

Start the discussion